Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.43 |
| ▸ | TDO2 | P48775 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CCR6 | P51684 | 1/20 | 0.40 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 4/20 | 0.40 |
| ▸ | MGAM | O43451 | 1/20 | 0.40 |
| ▸ | SI | P14410 | 1/20 | 0.40 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | DDX3X | O00571 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.39 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.39 |
| ▸ | CDK4 | P11802 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17210892 | 0.86 | DDX3X (0.48) | PTGS2IMPDH2LMNACCR6HKDC1 | |
| SCHEMBL17210881 | 0.84 | CCR6 (0.53) | IMPDH2LMNACCR6HKDC1GAA | |
| SCHEMBL19217082 | 0.84 | CAMK2D (0.46) | EIF2AK2PTGS2IMPDH2CCNE2CDK4 | |
| SCHEMBL15797140 | 0.82 | GSK3B (0.47) | EIF2AK2PTGS2IMPDH2LMNACCR6 | |
| SCHEMBL17211124 | 0.82 | CA1 (0.42) | EIF2AK2IMPDH2LMNACCR6HKDC1 | |
| SCHEMBL17210895 | 0.81 | PDE9A (0.51) | IMPDH2LMNACCR6HKDC1GAA | |
| SCHEMBL17211123 | 0.80 | CCR6 (0.47) | IMPDH2LMNACCR6HKDC1GAA | |
| SCHEMBL17210894 | 0.79 | IMPDH2 (0.65) | IMPDH2LMNACCR6HKDC1MEN1 | |
| SCHEMBL17210884 | 0.79 | GSK3B (0.50) | EIF2AK2PTGS2IMPDH2LMNACCR6 | |
| SCHEMBL19217081 | 0.78 | ROCK2 (0.40) | EIF2AK2TDO2PTGS2IMPDH2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9993463-B2 | Use of maleimide derivatives for preventing and treating cancer | CENTOGENE AG (DE) | 2018-06-12 | — | — | US | disclosed |
| US-9724331-B2 | Use of maleimide derivatives for preventing and treating leukemia | CENTOGENE AG (DE) | 2017-08-08 | — | — | US | disclosed |
| US-20150313882-A1 | USE OF MALEIMIDE DERIVATIVES FOR PREVENTING AND TREATING CANCER | CENTOGENE AG (DE) | 2015-11-05 | — | — | US | disclosed |
| US-20150306070-A1 | USE OF MALEIMIDE DERIVATIVES FOR PREVENTING AND TREATING LEUKEMIA | CENTOGENE AG (DE) | 2015-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150313882-A1 | USE OF MALEIMIDE DERIVATIVES FOR PREVENTING AND TREATING CANCER | MGMT, CBR3, IDH3A | EIF2AK2 4465/4885TDO2 767/4885PTGS2 2655/4885 |
| US-20150306070-A1 | USE OF MALEIMIDE DERIVATIVES FOR PREVENTING AND TREATING LEUKEMIA | MCL1, NPM1, FLI1 | EIF2AK2 3849/4885TDO2 1161/4885PTGS2 3075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.